Tokyo Tape
Sign in
← Chiome Bioscience

Annual report

4583.TEDINET S100QGF6
Period2022-01-01 → 2022-12-31
Filed2023-03-28
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 76
MetricValuePeriodScopeSource row
Revenue¥631m2022-01-01 → 2022-12-31StandaloneNet sales
Revenue¥713m2021-01-01 → 2021-12-31StandaloneNet sales
Revenue¥481m2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Revenue¥448m2019-01-01 → 2019-12-31dStandaloneNet sales (5-year summary)
Revenue¥213m2018-01-01 → 2018-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.3bn2022-01-01 → 2022-12-31StandaloneOperating income
Operating income−¥1.3bn2021-01-01 → 2021-12-31StandaloneOperating income
Ordinary income−¥1.2bn2022-01-01 → 2022-12-31StandaloneOrdinary income
Ordinary income−¥1.3bn2021-01-01 → 2021-12-31StandaloneOrdinary income
Ordinary income−¥1.3bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.4bn2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.5bn2018-01-01 → 2018-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.2bn2022-01-01 → 2022-12-31StandaloneIncome before income taxes
Profit before tax−¥1.5bn2021-01-01 → 2021-12-31StandaloneIncome before income taxes
Net income−¥1.2bn2022-01-01 → 2022-12-31StandaloneProfit loss
Net income−¥1.5bn2021-01-01 → 2021-12-31StandaloneProfit loss
Net income−¥1.3bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Net income−¥1.4bn2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Net income−¥1.5bn2018-01-01 → 2018-12-31dStandaloneNet income loss (5-year summary)
Total assets¥2.2bnat 2022-12-31StandaloneAssets
Total assets¥2.3bnat 2021-12-31StandaloneAssets
Total assets¥3.5bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥2.8bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total assets¥2.8bnat 2018-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥425mat 2022-12-31StandaloneLiabilities
Total liabilities¥446mat 2021-12-31StandaloneLiabilities
Net assets / equity¥1.8bnat 2022-12-31StandaloneNet assets
Net assets / equity¥1.9bnat 2021-12-31StandaloneNet assets
Net assets / equity¥3.1bnat 2020-12-31dStandaloneNet assets
Net assets / equity¥2.6bnat 2019-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥2.7bnat 2018-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥1.7bnat 2022-12-31StandaloneCash and deposits
Cash and deposits¥1.8bnat 2021-12-31StandaloneCash and deposits
Cash & equivalents¥1.7bnat 2022-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.8bnat 2021-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.7bnat 2020-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2019-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥2.3bnat 2018-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.2bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.1bn2021-01-01 → 2021-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.4bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.5bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.7bn2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥35m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥4m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥26m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.1bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥271m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.9bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.3bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥10m2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-28.262022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.742021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.062020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-44.612019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-57.262018-01-01 → 2018-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥36.7at 2022-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥45.55at 2021-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥77.99at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥78.1at 2019-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥98.89at 2018-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio80.2%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio79.4%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio88.2%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio92.6%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio93.5%at 2018-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued48,423,500at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued40,781,500at 2021-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued39,505,200at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued33,283,500at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued26,781,500at 2018-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees49at 2022-12-31StandaloneNumber of employees
Employees49at 2021-12-31StandaloneNumber of employees
Employees42at 2020-12-31dStandaloneNumber of employees
Employees38at 2019-12-31dStandaloneNumber of employees
Employees37at 2018-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 21
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment assetsat 2022-12-31¥2.2bn
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-12-31−¥472m
Drug Discovery And Developmentreportable segmentsegment profit2022-01-01 → 2022-12-31−¥1.1bn
Drug Discovery Supportreportable segmentrevenue2022-01-01 → 2022-12-31¥631m
Drug Discovery Supportreportable segmentrevenue external2022-01-01 → 2022-12-31¥631m
Drug Discovery Supportreportable segmentsegment profit2022-01-01 → 2022-12-31¥349m
—segment totalemployeesat 2022-12-3139 pure
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-12-31¥631m
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-12-31¥631m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-12-31−¥787m
Reconciling Itemsreconcilingsegment assetsat 2021-12-31¥2.3bn
Reconciling Itemsreconcilingsegment profit2021-01-01 → 2021-12-31−¥445m
Drug Discovery And Developmentreportable segmentrevenue2021-01-01 → 2021-12-31¥103m
Drug Discovery And Developmentreportable segmentrevenue external2021-01-01 → 2021-12-31¥103m
Drug Discovery And Developmentreportable segmentsegment profit2021-01-01 → 2021-12-31−¥1.2bn
Drug Discovery Supportreportable segmentrevenue2021-01-01 → 2021-12-31¥610m
Drug Discovery Supportreportable segmentrevenue external2021-01-01 → 2021-12-31¥610m
Drug Discovery Supportreportable segmentsegment profit2021-01-01 → 2021-12-31¥320m
Total Of Reportable Segments And Otherssegment totalrevenue2021-01-01 → 2021-12-31¥713m
Total Of Reportable Segments And Otherssegment totalrevenue external2021-01-01 → 2021-12-31¥713m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-01-01 → 2021-12-31−¥890m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 834
ItemContextValueUnit
Number of shares issued shares voting rightsCurrentYearInstant_SharesWithNoVotingRightsMember－
Number of shares issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember－
Number of shares issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember－
Number of voting rights issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember－
Number of shares issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember100
Number of shares issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember48412500
Number of voting rights issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember484125
Number of shares issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember10900
Number of shares issued shares voting rightsCurrentYearInstant48423500
Number of voting rights issued shares voting rightsCurrentYearInstant484125
Number of shares held in own name treasury shares etcCurrentYearInstant_Row1Member100
Number of shares held in others names treasury shares etcCurrentYearInstant_Row1Member－
Total number of shares held treasury shares etcCurrentYearInstant_Row1Member100
Shareholding ratio treasury shares etcCurrentYearInstant_Row1Member0.000
Number of shares held in own name treasury shares etcCurrentYearInstant100
Number of shares held in others names treasury shares etcCurrentYearInstant－
Total number of shares held treasury shares etcCurrentYearInstant100
Shareholding ratio treasury shares etcCurrentYearInstant0.000
Number of male directors and other officersFilingDateInstant8
Number of female directors and other officersFilingDateInstant－
Ratio of female directors and other officersFilingDateInstant－
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E26096-000KobayashiShigeruMember213600
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E26096-000BijohiraArihikoMember21800
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E26096-000TaokaShoseiMember10000
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E26096-000KoikeMasamichiMember－
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E26096-000KubotaHaruhisaMember－
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E26096-000KikuchiMatsuoMember－
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E26096-000YamakawaYoshiyukiMember－
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E26096-000SakamotoNiroMember－
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant245400
Audit fees reporting companyPrior1YearDuration25000000JPY
Non audit fees reporting companyPrior1YearDuration2500000JPY
Audit fees reporting companyCurrentYearDuration27500000JPY
Non audit fees reporting companyCurrentYearDuration－JPY
Total amount of remuneration etc remuneration etc by category of directors and other officersCurrentYearDuration_DirectorsExcludingOutsideDirectorsMember38993000JPY
Base remuneration remuneration etc by category of directors and other officersCurrentYearDuration_DirectorsExcludingOutsideDirectorsMember36750000JPY
Share option remuneration etc by category of directors and other officersCurrentYearDuration_DirectorsExcludingOutsideDirectorsMember－JPY
Bonus remuneration etc by category of directors and other officersCurrentYearDuration_DirectorsExcludingOutsideDirectorsMember－JPY
Restricted share awards remuneration etc by category of directors and other officersCurrentYearDuration_DirectorsExcludingOutsideDirectorsMember2243000JPY
Non monetary remuneration remuneration by category of directors and other officersCurrentYearDuration_DirectorsExcludingOutsideDirectorsMember2243000JPY
Number of directors and other officers remuneration etc by category of directors and other officersCurrentYearDuration_DirectorsExcludingOutsideDirectorsMember2
Total amount of remuneration etc remuneration etc by category of directors and other officersCurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember－JPY
Base remuneration remuneration etc by category of directors and other officersCurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember－JPY
Share option remuneration etc by category of directors and other officersCurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember－JPY
Bonus remuneration etc by category of directors and other officersCurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember－JPY
Restricted share awards remuneration etc by category of directors and other officersCurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember－JPY
Non monetary remuneration remuneration by category of directors and other officersCurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember－JPY
Number of directors and other officers remuneration etc by category of directors and other officersCurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember－
Total amount of remuneration etc remuneration etc by category of directors and other officersCurrentYearDuration_OutsideDirectorsAndOtherOfficersMember22800000JPY
Base remuneration remuneration etc by category of directors and other officersCurrentYearDuration_OutsideDirectorsAndOtherOfficersMember22800000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2021-12-31pass
balance sheet identitynon_consolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2020-12-31pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · operating cash flownon_consolidated 2021-01-01/2021-12-31pass
statement vs summary · operating cash flownon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · revenuenon_consolidated 2021-01-01/2021-12-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · total assetsnon_consolidated 2021-12-31pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass